Inhibition of IL-22 by neutralization antibodies has been shown to reduce the expression of chemotactic factors, decrease antimicrobial and hyperproliferative responses of keratinocytes, and prevent the development of imiquimod-induced psoriasis from skin inflammation (111). The gene discussed is IL22; the disease is psoriasis.